Sulfatinib

• CAT Number: I013757
• CAS Number: 1308672-74-3
• Molecular Formula: C₂₄H₂₈N₆O₃S
• Molecular Weight: 480.58
• Purity: ≥95%
• Target: FGFR
• Solubility: DMSO: ≥ 30 mg/mL
• IUPAC Name: N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide
• InChI: InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)
• InChIKey: TTZSNFLLYPYKIL-UHFFFAOYSA-N
• SMILES: CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C

Sulfatinib (Cat No.: I013757) is a potent, orally bioavailable inhibitor of tyrosine kinase receptors, including VEGFR1/2/3, FGFR1, and CSF1R. It exhibits strong anti-angiogenic and immunomodulatory properties, making it a promising therapeutic candidate for neuroendocrine tumors (NETs) and other solid tumors. Sulfatinib inhibits tumor growth by blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis and modulating tumor-associated macrophages via CSF1R inhibition. It has shown clinical efficacy in treating advanced NETs and is being explored for broader oncology applications in targeted cancer therapy.

Reference

[1]. PCT Int. Appl. (2011), WO 2011060746 A1 20110526.